A 15-year-old, woman, Crohn's disease patient, who carried the TPMT *3C heterozygous mutant, complained of alopecia 3 days after starting (Fig. 1) . After the episode, frequent clinical relapses led to infliximab therapy, which induced remission.
F i g u r e 1 . Cl i n i c a l c o u r s e . T h e p a t i e n t c o mp l a i n e d o f a l o p e c i a 3 d a y s a f t e r s t a r t i n g 6 -MP a n d t h e n d e v e l o p e d s e v e r e my e l o s u p p r e s s i o n 6 we e k s a f t e r s t a r t i n g 6 -MP . Ho we v e r , t h e p a t i e n t r e c o ve r e d f r o m my e l o s u p p r e s s i o n 2 we e k s a f t e r s t o p p i n g 6 -MP , t h o u g h t h e a l o p e c i a c o n t i n u e d f o r 6 we e k s . Af t e r t h e d e v e l o p me n t o f t h e s e s i d e e f f e c t s , t h e p a t i e n t a c h i e v e d t r a n s i e n t r e mi s s i o n o f h e r CD a n d c o n t i n u e d wi t h o u t E N f o r 1 8 we e k s .

Discussion
In the present case, alopecia developed shortly after the initiation of 6-MP before the development of severe myelosuppression. 6 is 0.8-1.6% , and the genotype is *1/*3C only in Japan (10, 11) . As compared with the wild type, TPMT activity was about 25% lower in a *1/*3C heterozygous mutant (12) . Lennard reported that knowledge of TPMT status warned of early bone marrow toxicity during the initial months of AZA therapy (13) . However, the effectiveness of initial testing for TPMT polymorphism remains uncertain. The 6-MP-induced severe myelosuppression in the present case may have been associated with a TPMT*3C heterozygous mutation.
